CANADA – Royal DSM venturing a Dutch multinational corporation active in the fields of health, nutrition and materials has pumped US$ 31.9m worth of investment into Brains Bioceutical corporation during an investment round and capital raise.

This major investment was made possible by Del Morgan & Co., an affiliate financial agent of Brains Bioceutical corporation.

Brains is among the leading identifiable companies that heavily ventures into cannabinoid (CBD) as an Active Pharmaceutical Ingredient (API) through research, development, production and clinical trials.

CBD, an active ingredient in cannabis is derived from the hemp plant and classified as medical marijuana which does not cause a ‘high’ as stated by the World Health organization (WHO).

Proven scientific research has shown that it can treat childhood epilepsy syndromes like Dravet syndrome and Lennox Gastaut syndrome (LGS).

The company is listed as the rare few drug companies within Europe to have the European Union Good Manufacturing and Distribution Practices (EU GMDP) certificate.

Brains manufactures CBD API for both human and veterinary use within a facility licensed under the Medicines and Healthcare products Regulatory Agency (MHRA).

Brains new investment is timely as it comes at a time when the global cannabidiol market is experiencing explosive growth.

According to Grand View Research, the global cannabidiol market size was valued at US$2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.

The market research firm notes the high demand for cannabidiol (CBD) for health and wellness purposes is one of the major factors behind this market growth.

In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products.

Brains is currently producing CBD API that has 99.7 % CBD and zero THC that is needed to help the healthcare and scientific community at a global level.

The company also recently launched its branded nutraceutical CBD, Brains Pure across several health and wellness retail stores in the UK.

It is planning to venture into the food production industry and is confident that it will be able to navigate the food requirements of the Food Standard Association (FSA) and the European Food Safety Authority (EFSA) for CBD related food products.

Brains hopes that the new and strategic partnership with DSM venturing enable it to take advantage of the existing opportunity in the CBD market and position it as the leading pharmaceutical company.